Show simple item record

5,6-Methylenedioxy-2-aminoindane : from laboratory curiosity to 'legal high'

dc.contributor.authorGallagher, C. T.
dc.contributor.authorAssi, S.
dc.contributor.authorStair, J. L.
dc.contributor.authorFergus, S.
dc.contributor.authorCorazza, Ornella
dc.contributor.authorCorkery, John
dc.contributor.authorSchifano, Fabrizio
dc.date.accessioned2012-08-15T14:01:06Z
dc.date.available2012-08-15T14:01:06Z
dc.date.issued2012-03-01
dc.identifier.citationGallagher , C T , Assi , S , Stair , J L , Fergus , S , Corazza , O , Corkery , J & Schifano , F 2012 , ' 5,6-Methylenedioxy-2-aminoindane : from laboratory curiosity to 'legal high' ' , Human Psychopharmacology: Clinical and Experimental , vol. 27 , no. 2 , pp. 106-112 . https://doi.org/10.1002/hup.1255
dc.identifier.issn1099-1077
dc.identifier.otherORCID: /0000-0002-7134-0665/work/70189317
dc.identifier.otherORCID: /0000-0001-7371-319X/work/98163979
dc.identifier.otherORCID: /0000-0002-2107-4522/work/141599674
dc.identifier.urihttp://hdl.handle.net/2299/8835
dc.descriptionMEDLINE® is the source for the MeSH terms of this document.
dc.description.abstractThe fully synthetic 'legal high' 5,6-methylenedioxy-2-aminoindane (MDAI) is an analogue of 3,4-methylenedioxymethamphetamine. Although developed in the 1990s, it was not widely abused until 2010. However, mephedrone was banned in the UK in April 2010, and almost immediately, MDAI was widely advertised as a legal alternative. This paper provides both an overview of the current state of knowledge of MDAI and a critical analysis of online available information relating to its psychoactive effects, adverse reactions and use in combination with other drugs.en
dc.format.extent7
dc.language.isoeng
dc.relation.ispartofHuman Psychopharmacology: Clinical and Experimental
dc.title5,6-Methylenedioxy-2-aminoindane : from laboratory curiosity to 'legal high'en
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionMedicinal and Analytical Chemistry
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionNanopharmaceutics
dc.contributor.institutionNatural Product Chemistry and Drug Design
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionPublic Health and Patient Safety Unit
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionCentre for Hazard Detection and Protection Research
dc.contributor.institutionCentre for Research in Mechanisms of Disease and Drug Discovery
dc.contributor.institutionCentre for Future Societies Research
dc.description.statusPeer reviewed
rioxxterms.versionofrecord10.1002/hup.1255
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record